Iridex Corp (NASDAQ:IRIX)
| Market Cap | $12.12M-22.2% |
| Revenue (ttm) | $51.57M+3.7% |
| Net Income | -$3.55M+34.9% |
| EPS | -$0.20+38.2% |
| Shares Out | 17.56M |
| PE Ratio | n/a |
| Forward PE | 34.50 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,597 |
| Open | $0.72 |
| Previous Close | $0.70 |
| Day's Range | $0.69 - $0.72 |
| 52-Week Range | $0.61 - $1.65 |
| Beta | 0.65 |
| Analysts | Buy |
| Price Target | $2.75(+298.55%) |
| Earnings Date | Nov 17, 2026 |
About IRIX
IRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions. The Cyclo G6 system is specifically engineered for glaucoma treatment. For ailments like diabetic macular edema and other retinal pathologies, IRIDEX provides the IQ 532 and IQ 577 laser photocoagulation systems. Furthermore, the OcuLight series, encompassing models such as TX, SL, SLx, GL, and GLx, offers solutions for managing severe retinal issues like proliferative diabetic retinopathy, macular holes, and retinal tears or detachments. Beyond laser consoles, the company also manufactures specialized delivery instruments. These include the TxCell scanning laser delivery system, which empowers clinicians with multi-spot pattern scanning capabilities. A unique slit lamp adapter enables practitioners to integrate standard slit lamps into their diagnostic and therapeutic workflows. Additionally, a laser indirect ophthalmoscope is available for interventions targeting peripheral retinal disorders. IRIDEX's offerings extend to various probes. The MicroPulse P3 Probe, when coupled with the Cyclo G6 laser system, facilitates MicroPulse transscleral laser therapy. For managing uncontrolled glaucoma, the G-Probe is employed, while both the G-Probe and G-Probe Illuminate are utilized in procedures addressing refractory glaucoma. The EndoProbe product line supports a range of vitrectomy procedures. Their diverse client base spans ophthalmology professionals, academic and research hospitals, government healthcare facilities, specialized surgical centers, general hospitals, veterinary clinics, and private medical practices. Product distribution is handled via an internal and independent sales network across the United States, supplemented by independent distributors for its international markets. Originally incorporated in 1989 as IRIS Medical Instruments, Inc., the company adopted the name IRIDEX Corporation in November 1995. Its corporate headquarters are situated in Mountain View, California.
Iridex Corp Stock Analysis — InsiderScore
Iridex Corp scored higher than 61% of companies evaluated by InsiderBuying, and ranked 17th out of 45 stocks in the healthcare sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Iridex Corp bought $15.0K of stock across 5 purchases in the last 90 days, the largest of them $5.0K.
The average purchase added about 3% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Nov 17, 2026Earnings report
$IRIX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in IRIX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IRIX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IRIX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
IRIX Revenue by Segment or Geography
| Retina | $6.49M | 51.61% |
| Cyclo G6 | $3.92M | 31.20% |
| Other | $2.16M | 17.20% |
As of: Q3 2026 (Jul 4, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New IRIX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IRIX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in IRIX
| VTIVanguard Morningstar Total Stock Market ETF | $253.17K |
| VXFVanguard Extended Market ETF | $71.03K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from IRIX’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
-10.0 since Sep 15Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
